4D Molecular Therapeutics Profiled in BioCentury

BioCentury, a leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government, has published an Emerging Company Profile on 4D Molecular Therapeutics. Co-founders David Schaffer and David Kirn discuss AAV gene therapy, the company’s directed evolution strategy, and the current partnership with uniQure.  The full profile can be found here (note: you must be a BioCentury subscriber to read the full article).